spacer
home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA)
WHITE PAPERS
logo_PRA_Healthk.jpg

PRA Health Sciences (PRA)

phone +44 (118) 918-1000
email prahealthsciences@prahs.com
web http://www.prahs.com
email Green Park, 500 South Oak Way, Reading, RG2 6AD UK

Biosimilars In Emerging Markets: Is It A Level Playing Field?

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
Biosimilars In Emerging Markets: Is It A Level Playing Field?
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Evolution Summit Press Release

“Many clinical trials today face delays because of difficulties in recruiting the required number of patients within the timeline. Sponsors need to look at other regions outside the US and Western Europe, that have access to a large pool of motivated patients, without compromising quality or anything else,” says Roman Hrynchuk, Chief Operating Officer, SanaClis. SanaClis was a solution provider at the Marcus Evans Evolution Summit March 2020.
More info >>


White Papers

Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement